Compare SDGR & MFIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDGR | MFIC |
|---|---|---|
| Founded | 1990 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2020 | 2004 |
| Metric | SDGR | MFIC |
|---|---|---|
| Price | $17.53 | $11.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $26.25 | $12.96 |
| AVG Volume (30 Days) | ★ 838.0K | 632.1K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 13.01% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.07 |
| Revenue | $256,951,000.00 | ★ $324,678,000.00 |
| Revenue This Year | $23.69 | $9.27 |
| Revenue Next Year | $20.46 | N/A |
| P/E Ratio | ★ N/A | $10.93 |
| Revenue Growth | ★ 32.90 | 11.35 |
| 52 Week Low | $15.99 | $10.18 |
| 52 Week High | $28.47 | $14.74 |
| Indicator | SDGR | MFIC |
|---|---|---|
| Relative Strength Index (RSI) | 43.56 | 42.72 |
| Support Level | $17.53 | $11.61 |
| Resistance Level | $19.04 | $12.02 |
| Average True Range (ATR) | 0.74 | 0.16 |
| MACD | 0.12 | -0.04 |
| Stochastic Oscillator | 24.77 | 14.06 |
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.